

mithra

Women's Health

Mission & Vision

Mithra is a Belgian **biotech company** dedicated to transforming **Women's Health** by offering new choices through innovation, with a focus on contraception and menopause.

Our goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span.


Founders




F. Fornieri, CEO

Prof. Dr. JM Foidart

At a Glance



Worldwide Markets



Why invest?

- Breakthrough innovation with the unique hormone **Estetrol (E4)**, **a native estrogen with an improved benefit/risk profile**
- 3 late-stage potential blockbusters, including **Estelle®**, a new era in Combined Oral Contraception on the market from 2021, **Donesta®**, the next generation of Hormone Therapy and **PeriNesta®**, the first potential complete oral treatment targeting perimenopause
- **Strong IP Position** with over 30 patent families
- Commercial **partnership strategy** with leaders in women's health
- **Multiple opportunities** beyond contraception and menopause
- Worldwide specialist in **long acting drug development** using polymer technology
- **Mithra CDMO**, industry partner with specialist R&D and manufacturing capabilities

Corporate strategy


To leverage the full potential of our E4 portfolio, and to develop partnering for our development and manufacturing technology platform.

Portfolio

	Product	Therapeutical area	Phase 1	Phase 2	Phase 3	Market approval
E4	Estelle®	<i>Contraception</i>				2021
	PeriNesta®	<i>Perimenopause</i>				2023
	Donesta®	<i>Menopause</i>				2023
	Under development	<i>CNS, dermatology, oncology, Covid19, etc.</i>	<i>Various stages of non-clinical development of future E4-based pipeline</i>			
			Formulation Clinical/BioEq.	Filing		Market approval
COMPLEX THERAPEUTICS	Myring™	<i>Contraception</i>	Europe			commercialized
			U.S.			2020
	Zoreline®	<i>Oncology</i>				2024
	Tibelia®	<i>Menopause</i>				commercialized


Share Structure

as of June 30, 2020




Stock Information

as of June 30, 2020




Financials


Revenues (€M)



EBITDA (€M)




Cash & Equivalents (€M)



Group Structure

Mithra Pharmaceuticals



* Neuralis as from 1/1/2021

2020 Financial calendar

- 9-Mar**
2019 Annual Results
- 22-Apr**
2019 Annual Report
- 22-May**
Annual General Meeting
- 24-Sep**
2020 Half Year Results

Analyst Coverage

- > **Berenberg**
Beatrice Allen
- > **Degroof Petercam**
Benoît Louage
- > **KBC**
Sandra Cauwenberghs
- > **Kempen**
Alexandru Cogut
- > **Kepler Cheuvreux**
Pierre-Alexandre Desir
- > **Portzamparc**
Christophe Dombu



Stay in touch!

Subscribe to our mailing list:
investors.mithra.com/en/contact/#subscribe